三氧化二砷
相扑蛋白
早幼粒细胞白血病蛋白
急性早幼粒细胞白血病
锌指
RNF4型
砷
化学
融合蛋白
癌症研究
泛素
维甲酸
生物化学
细胞生物学
转录因子
生物
基因
有机化学
重组DNA
作者
Xiaowei Zhang,Xiao-Jing Yan,Zi‐Ren Zhou,Feifei Yang,Ziyu Wu,Hongbin Sun,Wenxue Liang,Ai‐Xin Song,Valérie Lallemand-Breitenbach,Marion Jeanne,Qunye Zhang,Huai-Yu Yang,Qiuhua Huang,Guang‐Biao Zhou,Jianhua Tong,Yan Zhang,Jihui Wu,Hong‐Yu Hu,Hugues de Thé,Sai‐Juan Chen
出处
期刊:Science
[American Association for the Advancement of Science]
日期:2010-04-08
卷期号:328 (5975): 240-243
被引量:785
标识
DOI:10.1126/science.1183424
摘要
Arsenic, an ancient drug used in traditional Chinese medicine, has attracted worldwide interest because it shows substantial anticancer activity in patients with acute promyelocytic leukemia (APL). Arsenic trioxide (As2O3) exerts its therapeutic effect by promoting degradation of an oncogenic protein that drives the growth of APL cells, PML-RARalpha (a fusion protein containing sequences from the PML zinc finger protein and retinoic acid receptor alpha). PML and PML-RARalpha degradation is triggered by their SUMOylation, but the mechanism by which As2O3 induces this posttranslational modification is unclear. Here we show that arsenic binds directly to cysteine residues in zinc fingers located within the RBCC domain of PML-RARalpha and PML. Arsenic binding induces PML oligomerization, which increases its interaction with the small ubiquitin-like protein modifier (SUMO)-conjugating enzyme UBC9, resulting in enhanced SUMOylation and degradation. The identification of PML as a direct target of As2O3 provides new insights into the drug's mechanism of action and its specificity for APL.
科研通智能强力驱动
Strongly Powered by AbleSci AI